Fundz

AusperBio completes $120 million Series C financing led by a strategic investor to advance AHB-137 toward commercialization and expand next-generation HBV therapies.

PRIVATEAug 28, 2026

Amount Raised

$120 Million

Round Type

Series C

San MateoBiotechnologyHealth CareTherapeuticsBiopharma

Investors

Yuanbio Venture CapitalInnoPinnacle FundHankang CapitalCDH InvestmentsQiming Venture PartnersSherpa CapitalRA Capital Management

Description

AusperBio has closed its $120 million Series C financing. The round saw participation from new investor RA Capital Management and continued support from existing investors. The financing will support the development of AHB-137 and accelerate the company's pipeline expansion. This financing marks a significant milestone for AusperBio as it works on essential therapies for chronic hepatitis B.

Who to call at AusperBio, and when

A new round usually means AusperBio is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day AusperBio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at AusperBio, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at AusperBio. With Fundz connected, it knows.

See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

AusperBio

Location

San Mateo, California, United States

About

AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China, dedicated to advancing oligonucleotide and targeted delivery technologies for transformative therapies, with an initial focus on curing chronic hepatitis B. The company has developed a proprietary Med-OligoTM ASO platform with novel insights into ASO design and capabilities to substantially enhance the current ASO therapeutics. Combining with efficient targeted delivery conjugation technologies, the modular Med-OligosTM Platform empowers ASO therapeutics to treat broad viral infections, metabolic conditions, genetic disorders, and immune diseases.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment AusperBio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

4 contacts
Verified contactsGuofeng C., Co-Founder & CEO hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for AusperBio's next move

See what Strategic adds

AusperBio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.